Stereotactic radiation therapy in non–small cell lung cancer (NSCLC) patients with operable Stage I disease resulted in a 76% overall survival at three years. These findings were recently presented at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).
Lung cancer is a major cause of death worldwide, with over one million deaths per year. Non–small cell lung cancer (NSCLC) is the most common type of lung cancer. Early-stage NSCLC is most often treated with surgical resection with or without the addition of radiation therapy and/or chemotherapy. In some cases, patients may not be able to undergo surgery to remove their cancer due to underlying conditions such as emphysema or heart disease. Treatment of early-stage NSCLC patients who are unable to undergo surgery may include radiation therapy or observation. Strategies to improve treatment for this group of patients include stereotactic radiation therapy.
Stereotactic radiation therapy involves the very precise delivery of a large dose of radiation to a tumor while sparing normal tissue. Results from a study recently published in the Journal of the American Medical Association indicate that patients with early-stage NSCLC who were medically unable to undergo surgery to remove their cancer had a 55.8% overall survival at three years following stereotactic body radiation therapy. Researchers recently conducted a study to evaluate whether or not early-stage NSCLC patients eligible for surgery might also benefit from stereotactic radiation therapy.
In this Phase II Japanese study, researchers evaluated stereotactic radiation therapy among 65 patients with Stage I NSCLC that was considered operable. At three years, overall survival was 76% and progression-free survival was 54.5%. Side effects tended to be mild.
The researchers concluded that stereotactic radiation therapy is effective with few side effects and may provide Stage I NSCLC patients with an alternative to surgery, especially elderly patients.
 Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070-1076.
Copyright © 2016 CancerConsultants. All Rights Reserved.
[ viagra clone | augmentin 1000mg pills (brand) $327.00 | acyclovir 400mg pills $82.00 | prandin 1mg pills $87.00 | danazol 100mg pills $119.00 | prozac 20mg pills $132.00 | coversyl 2mg pills $70.00 | cialis 5mg pills $162.00 | cialis 10mg pills $180.00 | lexapro 20mg pills $91.00 | cialis 100 mg | maxolon 10mg pills $169.00 | adhd atomoxetine 18mg pills $212.00 | viagra soft 100mg pills $101.00 | viagra online kaufen | estrace 1mg pills $176.00 | noroxin 400mg pills $198.00 | protonix 40mg pills $123.00 | trazodone 100mg pills $158.00 | aspirin 75mg pills $68.00 | aricept 5mg pills $275.00 | motrin 600mg pills $89.00 | maxalt 10mg pills $206.00 | neurontin 300mg pills $167.00 | loxitane 25mg pills $262.00 | cytotec 200mg pills $71.00 | olmesartan 10mg pills $142.00 | fluticasone 125mcg inhaler $94.00 | is vigrx available in stores | exelon 6mg pills $203.00 | imdur 40mg pills $172.00 | cialis 20mg pills (brand) 20 $156.00 | zyprexa 15mg pills $244.00 | sitagliptin 100mg pills $122.00 | praziquantel 600mg pills $270.00 | viagra pills | anafranil 25mg pills 360 pills $387.00 | prograf 1mg pills $427.00 | atrovent 20mcg inhalation canister $84.00 | sublingual viagra pro 100mg pills $150.00 | prevacid 30mg pills $178.00 | augmentin 1000mg pills $165.00 | prograf 1mg pills $427.00 | combivir 300mg pills $207.00 | parlodel 1.25mg pills $239.00 | buying viagra in the us | vasotec 2.5mg pills $70.00 | pal pay pill viagra | topamax 25mg pills $114.00 | natural viagra | generic pack viagra | cardizem 60mg pills $104.00 | avelox 400mg pills $262.00 | priligy 60mg pills $142.00 ]
© Nebraska Hematology-Oncology | Web Design & Development by UNANIMOUS